Patents by Inventor Jeffrey T. McGrew

Jeffrey T. McGrew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240035037
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence or a human cytomegalovirus (huCMV) intron A sequence. Some of the vectors are useful for inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and methods of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Application
    Filed: July 3, 2023
    Publication date: February 1, 2024
    Applicant: Just-Evotec Biologics, Inc.
    Inventors: Jeffrey T. McGrew, James Joyce McDermott, Sherman Ku
  • Patent number: 11692193
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: July 4, 2023
    Assignee: Just-Evotec Biologies, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11685933
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: June 27, 2023
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11384140
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: July 12, 2022
    Assignee: Amgen Inc.
    Inventors: Randal Robert Ketchem, Jeffrey T. McGrew, Dina A. Fomina Yadlin
  • Publication number: 20220177916
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Application
    Filed: February 1, 2022
    Publication date: June 9, 2022
    Applicant: Just-Evotec Biologics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11261462
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: March 1, 2022
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11098310
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 24, 2021
    Assignee: JUST-EVOTEC BIOLOGICS, INC.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Publication number: 20210189403
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Application
    Filed: March 3, 2021
    Publication date: June 24, 2021
    Applicant: Just-Evotec Biologics, Inc
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Patent number: 11028410
    Abstract: A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 8, 2021
    Assignee: JUST-EVOTEC BIOLOGICS, INC.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Publication number: 20190185863
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 20, 2019
    Applicant: Just Biotherapeutics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Publication number: 20190185881
    Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Some of the vectors are useful for tetracycline-inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and a method of producing a protein of interest, in vitro, involving the mammalian host cell.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 20, 2019
    Applicant: Just Biotherapeutics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smidt, E-Ching Ong
  • Publication number: 20190127452
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Application
    Filed: May 11, 2017
    Publication date: May 2, 2019
    Applicant: AMGEN INC.
    Inventors: Randal Robert KETCHEM, Jeffrey T. MCGREW, Dina A. FOMINA YADLIN, Trent P. MUNRO, Neeraj Jagdish AGRAWAL, Kristine M. DARIS
  • Publication number: 20190055580
    Abstract: A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.
    Type: Application
    Filed: January 26, 2017
    Publication date: February 21, 2019
    Applicant: Just Biotherapeutics, Inc.
    Inventors: Jeffrey T. McGrew, Pauline S. Smitdt, E-Ching Ong
  • Publication number: 20140093915
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Application
    Filed: September 3, 2013
    Publication date: April 3, 2014
    Applicant: AMGEN INC.
    Inventors: DIRK E. SMITH, JOHN E. SIMS, JEFFREY T. MCGREW, MAREK Z. KUBIN, DUNCAN COCHRANE, LOUISE CONROY
  • Patent number: 8540993
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: September 24, 2013
    Assignee: AMGEN Inc.
    Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Publication number: 20130034569
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Application
    Filed: August 20, 2012
    Publication date: February 7, 2013
    Inventors: Dirk E. SMITH, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Patent number: 8257707
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: September 4, 2012
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Patent number: 7968313
    Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: June 28, 2011
    Assignee: Amgen Inc.
    Inventors: Jeffrey T. McGrew, Allison A. Bianchi
  • Publication number: 20110014201
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 20, 2011
    Applicant: AMGEN INC.
    Inventors: Dirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
  • Patent number: 7691605
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: April 6, 2010
    Assignee: Immunex Corporation
    Inventors: Jeffrey T. McGrew, Allison A. Bianchi